Ask us about IMC
The multi-collaborative Tumor Profiler Study
Read the Cancer Cell article “Tumor Profiler Study: Integrated multi-omic, functional tumor profiling for clinical decision support” and hear Bernd Bodenmiller discuss his lab’s role in this multi-site collaborative project. He hints at how technologies like IMC could be used to contribute to oncological clinical decision making in the future.
Enabling new precision medicine approaches in clinical oncology
Implications in breast cancer from the integration of phenotypic, molecular and drug response data were highlighted in a 2021 Nature Communications article “Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response.” Scientists at the Cancer Research UK Cambridge Institute in collaboration with the Imaging and Molecular Annotation of Xenografts and Tumors (IMAXT) consortium identified several previously undetected unique phenotypic profiles using data from a 33-marker breast cancer mass cytometry panel and suspension mass cytometry and IMC performed on the same xenograft samples. They identified phenotypic diversity that had not been previously detected using genomic or gene expression assessments. Read the press release to learn more about the implications for clinical relevance.
A possible link between pancreatic cancer treatment and inhibition of cadherin 11 signaling pathways
In the publication “Cadherin 11 promotes immunosuppression and extracellular matrix deposition to support growth of pancreatic tumors and resistance to gemcitabine in mice,” a research team led by scientists at Georgetown-Lombardi Comprehensive Cancer Center showed how loss or inhibition of cadherin 11 significantly extended survival of mice with pancreatic tumors by altering interactions between cancer-associated fibroblasts and immune cells, restoring sensitivity to gemcitabine. The ultimate impact of this study points to the potential to develop strategies to inhibit cadherin 11 or its signaling pathways. These strategies could support treatment of pancreatic cancer.
A new strategy could quell colorectal cancer metastasis to the liver
In the 2021 Cancer Cell publication “Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver,” Bertocchi et al. show that the PV-1 marker correlates with bacteria translocation and liver metastases and appears to serve as a prognostic marker for colorectal cancer distant recurrence and vascular impairment. This work offers insights to a new potential strategy to target tumor-associated bacteria to counteract liver metastases.
Contact us to ask about IMC
Contact us to get information about upcoming events, new products and more. You can also request a quote or ask to be contacted by your sales representative for a short discussion on how Imaging Mass Cytometry can help answer your challenging research questions.Contact us now
For Research Use Only. Not for use in diagnostic procedures.